Three independent discounted-cash-flow-style models value ADMA Biologics, Inc. every trading day. 0 of 3 currently price ADMA above its market price.
| Free Cash Flow model | $-3.12 |
| Excess Profit model | $4.94 |
| Residual Earnings model | $1.65 |
| Dividend Discount model | — |
| Piotroski F-Score | 6 / 9 |
| Return on invested capital | +27.5% |
| Net debt / EBITDA | -0.1× |
| Gross margin | +57.4% |
| Revenue CAGR | +49.0% |
| Cash conversion | 0.3× |
| Dividend yield | — |
| Buyback yield | -2.2% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open ADMA in StockKitty